These results raise the possibility that dopamine analogs could be repurposed to address critical unmet needs of lung cancer patients by augmenting efficacy and/or overcoming resistance to both anti‐EGFR and anti‐PD‐1 therapies. Here, EGFR is linked to lung carcinoma.